Logo

Indivior Receives Health Canada Approval for Sublocade (SC) (Buprenorphine Extended-Release) in Patients with Moderate to Severe Opioid Use Disorder(OUD)

Share this

Indivior Receives Health Canada Approval for Sublocade (SC) (Buprenorphine Extended-Release) in Patients with Moderate to Severe Opioid Use Disorder(OUD)

Shots:
  • The approval of Sublocade(qmt) in combination with medication-assisted treatment (MAT) is indicated to treat OUD in adults- using Atrigel delivery system
  • The clinical trials demonstrated- that Injection site reactions were reported in 16% of the patients. None of the injection site reactions were serious and one led to study treatment discontinuation
  • Health Canada has approved Sublocade- post USFDA approval in 30th Nov’2017- and will be available for patients in H2’19
/ article | Ref: Indivior | Image: Qualsys

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions